Teva and FTC reach settlement over ‘pay-for-delay’

Teva Pharmaceutical and the US Federal Trade Commission (FTC) have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

44 states accuse big pharma of price fixing generics market

13 May 2019 44 US states have filed a joint complaint against 20 drug companies, alleging they engaged in illegal conspiracies to “manipulate prices, reduce competition” and restrain trade for more than 100 generic drugs.

Big Pharma

Teva settles Sensipar patent dispute with Amgen

4 January 2019 Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.

Big Pharma

FTC agrees to re-open Actavis and Watson merger decision

19 December 2018 The Federal Trade Commission (FTC) has approved an application by pharmaceutical company Teva to re-open and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Teva and FTC reach settlement over ‘pay-for-delay’

More on this story

Editor's picks

Editor's picks

More features